CFH Region Deletion/Duplication Analysis by MLPA

Test Directory

Home Test Search Results CFH Region Deletion/Duplication Analysis by MLPA

Justification

Due to the homologous nature of these tandem genes, this complement-regulatory region is more susceptible to deletions and duplications. For example, rare deletions in this region that result in a fusion of the CFH gene to CFHR1 can cause atypical hemolytic uremic syndrome (aHUS). Other more common deletions of either CFHR3-1 or CFHR1-4 can be inherited such that many people are homozygous null for CFHR1; these people are more likely than others to develop anti-CFH antibodies, which can cause aHUS.

STAT: < 48 hours (M-F)

MLPA

Draw Tube: Purple Top

Sample Type: EDTA Whole Blood

Draw Kits Available

Specimen Requirements

	Sample Type	Volume Required	Minimum Volume	Stability
PREFERRED	EDTA Whole Blood	3mL	1mL	Room Temp.: 1 month Refrigerated: 1 month
ALTERNATIVE	Cheek swab	2 swab	-	Room Temp.: 1 month Refrigerated: 1 month

REJECTION CRITERIA	Sample contamination; sample compromised
SPECIAL INSTRUCTIONS	Post bone marrow transplant (post-BMT) patients require a cheek swab sample to test the transplant recipient; post-BMT patients require a venous blood sample to test the bone marrow donor.

General Information

METHODOLOGY	MLPA
STAT TAT	< 48 hours (M-F)
STAT TAT Performance	> 90% of results released in 48 hours
ROUTINE TAT	< 5 days (M-F)
ALTERNATIVE NAMES	CFH fusion, CFH/CFHR copy number variation (CNV) analysis, CFH, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5 deletion/duplication analysis, complement-mediated HUS, cm-HUS, TMA
DESCRIPTION	This test looks for deletions or duplications within the CFH, CFHR1, CFHR2, CFHR3, CFHR4 and CFHR5 genes by multiplex ligation-dependent probe amplification (MLPA), a method with much higher resolution than next-generation sequencing or microarrays.
LIMITATIONS	This test detects deletions and duplications but not balanced structural variants (i.e., inversions, insertions or translocations). This test requires two consecutive probes indicating a deletion or duplication to make a CNV call.
NORMAL RANGE	Interpretation: Negative
ASSOCIATED TESTING	-
REFERENCES	Venables JP, Strain L, Routledge D, et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 2006 Oct;3(10):e431. Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007 Mar 16;3(3):e41. Valoti E, Alberti M, Tortajada A, et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol. 2015 Jan;26(1):209-19.
SAMPLE REPORT	Upon request
NEW YORK STATE APPROVED	No

Test Codes

ORDER CODE	P3410
CPT CODE	81479
LOINC CODE	51779-7